ALLENTOWN, Pa. — U.S. Specialty Formulations announced Wednesday it plans to bring a local economic boost to the Lehigh Valley with a $15 million expansion to its biopharma facility.
With $4.7 million backing in hand, the pharmaceutical company said the expansion will bring "new facility clean room suites and state-of-the-art automated packaging and product inspection equipment," that will let the company take on larger projects.
And with it, more than 100 employees to the Allentown facility.
"This expansion is a transformative step for USSF."Kyle Flanigan, CEO and co-founder of US Specialty Formulations
The funding will let USSF, at 1401 S. Albert St., Allentown, increase its clean room production capacity more than 2.5 times, the company said.
Its website said batch sizes range from 10-30,000 vials.
'A transformative step'
USSF provides materials and services for clinical materials (investigational new drugs), preclinical materials, stability programs, private label formulations and packaging and formulation development and scale-up, according to its website.
It also provides clinical supplies and manufacturing of products such as sterile vials and bottles, pre-filled syringes and single- and multi-chamber intravenous bags.
In simpler terms: USSF manufactures medications and vaccines.
The expansion of the company is expected to be completed by the end of 2025, according to a release.
USSF co-founder Kyle Flanigan, its chief executive officer, said the multimillion-dollar growth raises the bar for the company and reaffirms its commitment to risk-reducing pharmaceutical solutions.
"This expansion is a transformative step for USSF," Flanigan said in a release. "This expansion empowers our dedicated team to serve our partners and clients worldwide more effectively."
